Photo of Ann Mullally,  MD

Ann Mullally, MD

Brigham And Women's Hospital

Brigham And Women's Hospital
Phone: (617) 355-9002


amullally@partners.org

Ann Mullally, MD

Brigham And Women's Hospital

EDUCATIONAL TITLES

  • Assistant Professor, Medicine, Harvard Medical School
  • Attending Physician , Leukemia Program, Medical Oncology, Dana-Farber Cancer Institute
  • Associate Physician, Hematology, Brigham And Women's Hospital

DF/HCC PROGRAM AFFILIATION

Research Abstract

I am a translational cancer researcher in the field of myeloid malignancies, with a focus on myeloproliferative neoplasms (MPN). My laboratory studies the biology, genetics, and therapy of myeloid cancers using primary human samples, murine models and multiple in vitro model systems. We used standard biochemical assays, proteomics, multi-parameter flow cytometry, single cell mass cytometry, in vivo functional genomics (including CRISPR) and next generation sequencing technologies. Current projects in my laboratory are focused on hematopoietic-stromal interactions in the context of myelofibrosis, the biology of mutant calreticulin in MPN, the differential molecular dependencies and bone marrow niche interactions of disease-propagating stem cells in myeloid cancers, identification of heritability alleles for familial MPN. My laboratory is actively expanding currently so please contact me if you are an exceptionally motivated post-doctoral candidate interested in joining my group.

Publications

Powered by Harvard Catalyst
  • Schram AM, Campigotto F, Mullally A, Fogerty A, Massarotti E, Neuberg D, Berliner N. Marked hyperferritinemia does not predict for HLH in the adult population. Blood 2015; 125:1548-52. PubMed
  • Bender M, Giannini S, Grozovsky R, Jönsson T, Christensen H, Pluthero FG, Ko A, Mullally A, Kahr WH, Hoffmeister KM, Falet H. Dynamin 2-dependent endocytosis is required for normal megakaryocyte development in mice. Blood 2015; 125:1014-24. PubMed
  • Ishikawa Y, Maeda M, Pasham M, Aguet F, Tacheva-Grigorova SK, Masuda T, Yi H, Lee SU, Xu J, Teruya-Feldstein J, Ericsson M, Mullally A, Heuser J, Kirchhausen T, Maeda T. Role of the clathrin adaptor PICALM in normal hematopoiesis and polycythemia vera pathophysiology. Haematologica 2015. PubMed
  • Chen E, Mullally A. How does JAK2V617F contribute to the pathogenesis of myeloproliferative neoplasms? Hematology Am Soc Hematol Educ Program 2015; 2014:268-76. PubMed
  • Järås M, Miller PG, Chu LP, Puram RV, Fink EC, Schneider RK, Al-Shahrour F, Peña P, Breyfogle LJ, Hartwell KA, McConkey ME, Cowley GS, Root DE, Kharas MG, Mullally A, Ebert BL. Csnk1a1 inhibition has p53-dependent therapeutic efficacy in acute myeloid leukemia. J Exp Med 2014; 211:605-12. PubMed
  • De Vita S, Schneider RK, Garcia M, Wood J, Gavillet M, Ebert BL, Gerbaulet A, Roers A, Levine RL, Mullally A, Williams DA. Loss of function of TET2 cooperates with constitutively active KIT in murine and human models of mastocytosis. PLoS ONE 2014; 9:e96209. PubMed
  • Mullally A, Ebert BL. Sinister symbiosis: pathological hematopoietic-stromal interactions in CML. Cell Stem Cell 2013; 13:257-8. PubMed
  • Mullally A, Bruedigam C, Poveromo L, Heidel FH, Purdon A, Vu T, Austin R, Heckl D, Breyfogle LJ, Kuhn CP, Kalaitzidis D, Armstrong SA, Williams DA, Hill GR, Ebert BL, Lane SW. Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-留 in a murine model of polycythemia vera. Blood 2013; 121:3692-702. PubMed
  • Mullally A, Ebert BL. Janus reveals another face: the biologic rationale for targeting janus kinase 2 in lymphoma. J Clin Oncol 2012; 30:4168-70. PubMed
  • Mullally A, Lane SW, Brumme K, Ebert BL. Myeloproliferative neoplasm animal models. Hematol Oncol Clin North Am 2012; 26:1065-81. PubMed
  • Koppikar P, Bhagwat N, Kilpivaara O, Manshouri T, Adli M, Hricik T, Liu F, Saunders LM, Mullally A, Abdel-Wahab O, Leung L, Weinstein A, Marubayashi S, Goel A, Gönen M, Estrov Z, Ebert BL, Chiosis G, Nimer SD, Bernstein BE, Verstovsek S, Levine RL. Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature 2012; 489:155-9. PubMed
  • Mullally A, Poveromo L, Schneider RK, Al-Shahrour F, Lane SW, Ebert BL. Distinct roles for long-term hematopoietic stem cells and erythroid precursor cells in a murine model of Jak2V617F-mediated polycythemia vera. Blood 2012; 120:166-72. PubMed
  • Mullally A, Ebert BL. STATistical power of clonal analysis: differential STAT1 pathway activation downstream of the JAK2V617F mutation. Cancer Cell 2010; 18:405-6. PubMed
  • Housman E, Chang P, Lane SW, Blinder R, Galinsky I, Kesari S, Ho VT, Stone RM, Mullally A. CNS relapse in acute promyeloctyic leukemia. J Clin Oncol 2010; 28:e409-11. PubMed
  • Mullally A, Ebert BL. NF1 inactivation revs up Ras in adult acute myelogenous leukemia. Clin Cancer Res 2010; 16:4074-6. PubMed
  • Mullally A, Lane SW, Ball B, Megerdichian C, Okabe R, Al-Shahrour F, Paktinat M, Haydu JE, Housman E, Lord AM, Wernig G, Kharas MG, Mercher T, Kutok JL, Gilliland DG, Ebert BL. Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. Cancer Cell 2010; 17:584-96. PubMed
  • Abdel-Wahab O,Mullally A,Hedvat C,Garcia-Manero G,Patel J,Wadleigh M,Malinge S,Yao J,Kilpivaara O,Bhat R,Huberman K,Thomas S,Dolgalev I,Heguy A,Paietta E,Le Beau MM,Beran M,Tallman MS,Ebert BL,Kantarjian HM,Stone RM,Gilliland DG,Crispino JD,Levine RL. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 2009; 114:144-7. PubMed
  • Kilpivaara O,Mukherjee S,Schram AM,Wadleigh M,Mullally A,Ebert BL,Bass A,Marubayashi S,Heguy A,Garcia-Manero G,Kantarjian H,Offit K,Stone RM,Gilliland DG,Klein RJ,Levine RL. A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. Nat Genet 2009; 41:455-9. PubMed
  • Mullally A, Ritz J. Beyond HLA: the significance of genomic variation for allogeneic hematopoietic stem cell transplantation. Blood 2006; 109:1355-62. PubMed
  • Mullally AM, Vogelsang GB, Moliterno AR. Wasted sheep and premature infants: the role of trace metals in hematopoiesis. Blood Rev. 2004; 18:227-34. PubMed
Hide